Evidence map›Paper›PMID 29157295›Full record

ArticleJournal for immunotherapy of cancer2017

Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.

Qiong Xue, Emily Bettini, Patrick Paczkowski, Colin Ng, Alaina Kaiser, Timothy McConnell, Olja Kodrasi, Máire F Quigley, James Heath, Rong Fan and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 122 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Single-Cell Protein Assays in Context: From 2D to 3D and In Situ Analysis.Annual review of analytical chemistry (Palo Alto, Calif.) · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Qiong XueNovartis Pharmaceuticals, 64 Sidney Street, Cambridge, MA, 02139, USA. chelsea.xue@novartis.com.
Emily BettiniIsoPlexis Corporation, 35 NE Industrial Rd, Branford, CT, 06405, USA.
Patrick PaczkowskiIsoPlexis Corporation, 35 NE Industrial Rd, Branford, CT, 06405, USA.
Colin NgIsoPlexis Corporation, 35 NE Industrial Rd, Branford, CT, 06405, USA.
Alaina KaiserIsoPlexis Corporation, 35 NE Industrial Rd, Branford, CT, 06405, USA.
Timothy McConnellIsoPlexis Corporation, 35 NE Industrial Rd, Branford, CT, 06405, USA.
Olja KodrasiNovartis Pharmaceuticals, 64 Sidney Street, Cambridge, MA, 02139, USA.
Máire F QuigleyNovartis Pharmaceuticals, 64 Sidney Street, Cambridge, MA, 02139, USA.
James HeathNanoSystems Biology Cancer Center, Division of Chemistry, California Institute of Technology, Pasadena, CA, 91125, USA.
Rong FanDepartment of Biomedical Engineering, Yale University, New Haven, CT, 06520, USA.
Sean MackayIsoPlexis Corporation, 35 NE Industrial Rd, Branford, CT, 06405, USA.
Mark E DudleyNovartis Pharmaceuticals, 64 Sidney Street, Cambridge, MA, 02139, USA.
Sadik H KassimNovartis Pharmaceuticals, 64 Sidney Street, Cambridge, MA, 02139, USA.
Jing ZhouIsoPlexis Corporation, 35 NE Industrial Rd, Branford, CT, 06405, USA. jing@isoplexis.com.
IsoPlexis (United States) · USNovartis (France) · FRCalifornia Institute of Technology · USYale University · US

Funding

Precision quality check of immunotherapeutics via single-cell cytokine mappingR44CA210841 · NCI · ISOPLEXIS, INC. · PI MCCONNELL, TIMOTHY S, ZHOU, JING · 2017 to 2021
$5.9M
NCI NIH HHS R44 CA210841
6 · The paper itself

Abstract

backgroundIt remains challenging to characterize the functional attributes of chimeric antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and immunotoxicity ex vivo, despite promising in vivo efficacy in patients with B cell malignancies.

methodsWe employed a single-cell, 16-plex cytokine microfluidics device and new analysis techniques to evaluate the functional profile of CD19 CAR-T cells upon antigen-specific stimulation. CAR-T cells were manufactured from human PBMCs transfected with the lentivirus encoding the CD19-BB-z transgene and expanded with anti-CD3/anti-CD28 coated beads. The enriched CAR-T cells were stimulated with anti-CAR or control IgG beads, stained with anti-CD4 RPE and anti-CD8 Alexa Fluor 647 antibodies, and incubated for 16 h in a single-cell barcode chip (SCBC). Each SCBC contains ~12,000 microchambers, covered with a glass slide that was pre-patterned with a complete copy of a 16-plex antibody array. Protein secretions from single CAR-T cells were captured and subsequently analyzed using proprietary software and new visualization methods.

resultsWe demonstrate a new method for single-cell profiling of CD19 CAR-T pre-infusion products prepared from 4 healthy donors. CAR-T single cells exhibited a marked heterogeneity of cytokine secretions and polyfunctional (2+ cytokine) subsets specific to anti-CAR bead stimulation. The breadth of responses includes anti-tumor effector (Granzyme B, IFN-γ, MIP-1α, TNF-α), stimulatory (GM-CSF, IL-2, IL-8), regulatory (IL-4, IL-13, IL-22), and inflammatory (IL-6, IL-17A) functions. Furthermore, we developed two new bioinformatics tools for more effective polyfunctional subset visualization and comparison between donors.

conclusionsSingle-cell, multiplexed, proteomic profiling of CD19 CAR-T product reveals a diverse landscape of immune effector response of CD19 CAR-T cells to antigen-specific challenge, providing a new platform for capturing CAR-T product data for correlative analysis. Additionally, such high dimensional data requires new visualization methods to further define precise polyfunctional response differences in these products. The presented biomarker capture and analysis system provides a more sensitive and comprehensive functional assessment of CAR-T pre-infusion products and may provide insights into the safety and efficacy of CAR-T cell therapy.

Indexed as

Antigens, CD19CytokinesFemaleHumansMaleReceptors, Antigen, T-CellAntigens, CD19CytokinesReceptors, Antigen, T-CellCD19 CAR-T cell productMicrofluidic microdevicePolyfunctionalityPrecision profilingSingle-cell proteomics

Identifiers

PMID29157295
PMCPMC5697351
OpenAlexW2766877982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.